Drug Trial Radar · NCT00034788
A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX
Last checked: Nov 20, 2026Latest source record: Jun 8, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
84
Actual
Start
Dec 2000
Primary completion
Not stated
Study completion Feb 2004
Sponsor
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- May 3, 2002
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of REGRANEX® Gel compared with placebo when applied for up to 52 consecutive weeks to recurring or non-healing ulcers of the ankle or foot related to diabetes.
Conditions
- Foot Ulcer
- Diabetic Foot
- Skin Ulcer
- Diabetic Neuropathies
Interventions
BecaplerminDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to complete ulcer healing.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.